Laura Duran-Lozano

Laura Duran-Lozano

Auto-generated profile, based on publicly available information

Laura Duran-Lozano

Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund, Sweden

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2018 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
SBSandra Bonache
Sandra Bonache
IEIrene Esteban
Irene Esteban
AMAlejandro Moles-Fernández
Alejandro Moles-Fernández
ATAnna Tenés
Anna Tenés
LDLaura Duran-Lozano
Laura Duran-Lozano
ODOrland Diez
Orland Diez

5 September 2018 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
AMAlejandro Moles-Fernández
Alejandro Moles-Fernández
LDLaura Duran-Lozano
Laura Duran-Lozano
GMGemma Montalban
Gemma Montalban
SBSandra Bonache
Sandra Bonache
ILIrene López-Perolio
Irene López-Perolio
Sara Gutiérrez-EnríquezSara Gutiérrez-Enríquez
Sara Gutiérrez-Enríquez
In silico tools for splicing defect prediction have a key role to assess the impact of variants of uncertain significance. Our aim was to evaluate the performance of a set of commonly used splicing in silico tools comparing the predictions against RNA in vitro results. This was done for natural splice sites of clinically relevant genes in hereditary breast/ovarian cancer (HBOC) and Lynch syndrome. A study divided into two stages was used to evaluate SSF-like, MaxEntScan, NNSplice, HSF, SPANR, and dbscSNV tools. A discovery dataset of 99 variants with unequivocal results of RNA in vitro studies, located in the 10 exonic and 20 intronic nucleotides adjacent to exon–intron boundaries of BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, ATM, BRIP1, CDH1, PALB2, PTEN, RAD51D, STK11, and TP53, was collected from four Spanish cancer genetic laboratories. The best stand-alone predictors or combinations were validated with a set of 346 variants in the same genes with clear splicing outcomes reported in the literature. Sensitivity, specificity, accuracy, negative predictive value (NPV) and Mathews Coefficient Correlation (MCC) scores were used to measure the performance. The discovery stage showed that HSF and SSF-like were the most accurate for variants at the donor and acceptor region, respectively. The further combination analysis revealed that HSF, HSF+SSF-like or HSF+SSF-like+MES achieved a high performance for predicting the disruption of donor sites, and SSF-like or a sequential combination of MES and SSF-like for predicting disruption of acceptor sites. The performance confirmation of these last results with the validation dataset, indicated that the highest sensitivity, accuracy, and NPV (99.44%, 99.44%, and 96.88, respectively) were attained with HSF+SSF-like or HSF+SSF-like+MES for donor sites and SSF-like (92.63%, 92.65%, and 84.44, respectively) for acceptor sites. We provide recommendations for combining algorithms to conduct in silico splicing analysis that achieved a high performance. The high NPV obtained allows to select the variants in which the study by in vitro RNA analysis is mandatory against those with a negligible probability of being spliceogenic. Our study also shows that the performance of each specific predictor varies depending on whether the natural splicing sites are donors or acceptors.

19 April 2021 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
LDLaura Duran-Lozano
Laura Duran-Lozano
GTGudmar Thorleifsson
Gudmar Thorleifsson
APAitzkoa Lopez de Lapuente Portilla
Aitzkoa Lopez de Lapuente Portilla
ANAbhishek Niroula
Abhishek Niroula
MWMolly Went
Molly Went
BNBjörn Nilsson
Björn Nilsson
Multiple myeloma (MM) is caused by the uncontrolled, clonal expansion of plasma cells. While there is epidemiological evidence for inherited susceptibility, the molecular basis remains incompletely understood. We report a genome-wide association study totalling 5,320 cases and 422,289 controls from four Nordic populations, and find a novel MM risk variant at SOHLH2 at 13q13.3 (risk allele frequency = 3.5%; odds ratio = 1.38; P = 2.2 × 10−14). This gene encodes a transcription factor involved in gametogenesis that is normally only weakly expressed in plasma cells. The association is represented by 14 variants in linkage disequilibrium. Among these, rs75712673 maps to a genomic region with open chromatin in plasma cells, and upregulates SOHLH2 in this cell type. Moreover, rs75712673 influences transcriptional activity in luciferase assays, and shows a chromatin looping interaction with the SOHLH2 promoter. Our work provides novel insight into MM susceptibility.

14 December 2018 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
LDLaura Duran-Lozano
Laura Duran-Lozano
GMGemma Montalban
Gemma Montalban
SBSandra Bonache
Sandra Bonache
AMAlejandro Moles-Fernández
Alejandro Moles-Fernández
ATAnna Tenés
Anna Tenés
ODOrland Diez
Orland Diez

16 November 2021 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
LDLaura Duran-Lozano
Laura Duran-Lozano
GTGudmar Thorleifsson
Gudmar Thorleifsson
APAitzkoa Lopez de Lapuente Portilla
Aitzkoa Lopez de Lapuente Portilla
ANAbhishek Niroula
Abhishek Niroula
MWMolly Went
Molly Went
BNBjörn Nilsson
Björn Nilsson